REVTORPYK Drug Patent Profile
✉ Email this page to a colleague
When do Revtorpyk patents expire, and when can generic versions of Revtorpyk launch?
Revtorpyk is a drug marketed by Celcuity and is included in one NDA.
The generic ingredient in REVTORPYK is gedatolisib. One supplier is listed for this compound. Additional details are available on the gedatolisib profile page.
US Patents and Regulatory Information for REVTORPYK
REVTORPYK is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of REVTORPYK is ⤷ Start Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celcuity | REVTORPYK | gedatolisib | POWDER;INTRAVENOUS | 219908-001 | Jul 14, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
